Suppr超能文献

丝裂原活化蛋白激酶激活的蛋白激酶2与胶质瘤患者的不良预后及胶质瘤中的免疫抑制相关。

MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma.

作者信息

Sun Jinmin, Wu Sicheng, Zhao Wenyu, Xue Senrui, Zhang Lei, Ren Jing

机构信息

Jiangsu Key Laboratory of Brain Disease Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Laboratory of Clinical and Experimental Pathology, Department of Pathology, Xuzhou Medical University, Xuzhou, Jiangsu, China.

出版信息

Front Oncol. 2024 Jan 23;14:1307992. doi: 10.3389/fonc.2024.1307992. eCollection 2024.

Abstract

INTRODUCTION

An effective therapeutic method to noticeably improve the prognosis of glioma patients has not been developed thus far. MAPK-activated protein kinase 2 (MAPKAPK2) is a serine/threonine kinase, which is involved in tumorigenesis, tumor growth, metastasis, and the inflammatory process. The clinical significance and molecular function of MAPKAPK2 in glioma remain unclear.

METHODS

MAPKAPK2 expression in human glioma tissues was detected by immunohistochemistry and analyzed from the transcriptome sequencing data in TCGA and CGGA. Prognostic nomogram was constructed to predict the survival risk of individual patients. GO and KEGG enrichment analyses were performed to analyze the function and pathways MAPKAPK2 involved. Single-cell RNA sequencing data was used to analyze the cell types in which MAPKAPK2 was enriched. Flow cytometry was used for cell cycle and apoptosis detection. The ability of cell proliferation and migration was analyzed by CCK8 and cell migration assay, respectively. Correlation analyses were performed to analyze the relationship of MAPKAPK2 with immune infiltration, immune regulators, chemokine, and chemokine receptors.

RESULTS

MAPKAPK2 was not only aberrantly upregulated in glioma tissues but also correlated with poor clinical characteristics. Moreover, MAPKAPK2 was prevalent in isocitrate dehydrogenase (IDH) wild-type and 1p/19q non-codeletion glioma cohorts and predicted poor prognosis of glioma patients. MAPKAPK2 may be involved in cell proliferation, cell migration, DNA damage repair, and immune regulation in glioma. MAPKAPK2 was enriched in microglia/macrophages and malignant tumor cells. Further investigation into cellular function revealed that inhibiting MAPKAPK2 suppressed the proliferation and migration of glioblastoma multiforme (GBM) cells in vitro. The inhibition of MAPKAPK2 significantly induced the G1 cell cycle arrest and cell apoptosis of GBM cells. Consistent with the enriched function of MAPKAPK2 in immune regulation, MAPKAPK2 was correlated with immune cell infiltration in glioma tissues. Mechanistically, a series of immune regulators, immunomodulatory chemokine, and chemokine receptors were positively correlated with MAPKAPK2 expression.

DISCUSSION

Our findings provide evidence of the clinical relevance of MAPKAPK2 in prognosis evaluation of glioma patients and highlight the underlying significance of MAPKAPK2 in glioma therapy.

摘要

引言

迄今为止,尚未开发出一种能显著改善胶质瘤患者预后的有效治疗方法。丝裂原活化蛋白激酶激活的蛋白激酶2(MAPKAPK2)是一种丝氨酸/苏氨酸激酶,参与肿瘤发生、肿瘤生长、转移和炎症过程。MAPKAPK2在胶质瘤中的临床意义和分子功能仍不清楚。

方法

采用免疫组织化学法检测人胶质瘤组织中MAPKAPK2的表达,并根据TCGA和CGGA中的转录组测序数据进行分析。构建预后列线图以预测个体患者的生存风险。进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,以分析MAPKAPK2涉及的功能和途径。利用单细胞RNA测序数据分析MAPKAPK2富集的细胞类型。采用流式细胞术检测细胞周期和细胞凋亡。分别通过CCK8和细胞迁移实验分析细胞增殖和迁移能力。进行相关性分析,以分析MAPKAPK2与免疫浸润、免疫调节因子、趋化因子和趋化因子受体的关系。

结果

MAPKAPK2不仅在胶质瘤组织中异常上调,而且与不良临床特征相关。此外,MAPKAPK2在异柠檬酸脱氢酶(IDH)野生型和1p/19q非共缺失胶质瘤队列中普遍存在,并预测胶质瘤患者预后不良。MAPKAPK2可能参与胶质瘤的细胞增殖、细胞迁移、DNA损伤修复和免疫调节。MAPKAPK2在小胶质细胞/巨噬细胞和恶性肿瘤细胞中富集。对细胞功能的进一步研究表明,抑制MAPKAPK2可在体外抑制多形性胶质母细胞瘤(GBM)细胞的增殖和迁移。抑制MAPKAPK2可显著诱导GBM细胞的G1期细胞周期阻滞和细胞凋亡。与MAPKAPK2在免疫调节中的富集功能一致,MAPKAPK2与胶质瘤组织中的免疫细胞浸润相关。机制上,一系列免疫调节因子、免疫调节趋化因子和趋化因子受体与MAPKAPK2表达呈正相关。

讨论

我们的研究结果为MAPKAPK2在胶质瘤患者预后评估中的临床相关性提供了证据,并突出了MAPKAPK2在胶质瘤治疗中的潜在意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6867/10844562/c1202381f2a4/fonc-14-1307992-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验